IMBiologics inks $964 mn license deal with U.S. firm

2024. 6. 18. 10:39
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Courtesy of IMBiologics]
South Korean antibody drug startup IMBiologics announced on Monday that it signed a license deal for two autoimmune disease treatment candidates with Navigator Medicines in the United States.

The contract is valued at about 1.3 trillion won ($964 million), inclusive of upfront payments and milestone-based fees.

The treatment candidates were co-developed by IMBiologics in partnership with two other Korean companies, HK inno.N and YBiologics, with that deal including an upfront payment of $20 million and additional milestone payments totaling up to $944.75 million. Royalties based on annual net sales post-commercialization are not included in this figure.

The transferred substances are IMB-101, a bispecific antibody targeting both the autoimmune disease antibody OX40L and tumor necrosis factor (TNF), and IMB-102, a monospecific antibody that only targets OX40L.

Under the agreement, Navigator Medicines will hold the rights to develop and commercialize these candidates globally outside Asia but including Japan.

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?